We recently published a list of 10 Defensive Stocks Billionaire Ken Fisher is Betting On. In this article, we are going to ...

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Merck & Company (MRK – Research ...

Use of University of Minnesota Morris wordmarks and logos must conform to current policies and guidelines. See the Graphic Identity Guidelines for more information. These logos have specific uses and ...

This article examines post-market drug safety, highlighting surveillance mechanisms, regulatory responses, and case studies of approved drugs with hidden risks.

TD Cowen analyst Steve Scala maintained a Hold rating on Merck & Company (MRK – Research Report) today and set a price target of $100.00.

Adcendo, a biotech company pioneering the development of first- and potential best-in-class antibody-drug conjugates (ADCs) ...

Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a cardioprotective benefit won’t be answered until Phase 3 tests read out.

Traders nervously awaited “Liberation Day” on Wednesday, April 2, when the Trump administration’s tariffs are scheduled to go ...

Merck & Co. Inc. closed 33.72% short of its 52-week high of $134.63, which the company achieved on June 25th.

The global Analytical Standards Market, valued at US$1.44 billion in 2022, is forecasted to grow at a robust CAGR of 5.9%, ...

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...

Merck released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA ...